News Source:- >> | Image Source:- >>

ImmunityBio announced that the U.S. Food and Drug Administration has accepted its Biologics License Application (BLA) for N-803, a specific form of bladder cancer. N-803 is an antibody cytokine fusion protein. The BLA is for the use of the drug with Bacillus Calmette-Guerin (BCG) to treat patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma (NMIBC) in situ (CIS) with or without Ta or T1 disease. ImmunityBio’s N-803 has received Breakthrough therapy and fast-track designations by the FDA for BCG-unresponsive NMIBC CIS and Fast Track designation for BCG-unresponsive NMIBC papillary and BCG-naive NMIBC CIS,

=========================================================================================================

About Ingenious e-Brain:-

Ingenious e-Brain provides high-quality, customized, and cost-effective Technology Research, Business Research, and Intellectual Property Research solutions to industry leaders and innovative companies across the globe. Innovation, knowledge, and transparency form the basis of our company’s mission and vision. Along with cost benefits, we provide the highest quality results ensuring fool-proof confidentiality and security. We are an ISO-certified company with offices in India and USA.

Ingenious e-Brain has a strong team of analysts and subject matter experts with domain proficiency which is devoted to helping clients grow. Our highly qualified professionals offer tailored, value-added, and cost-effective services to our clients. We believe in building long-term relationships with our clients which include national and international corporations, Fortune 500 companies, the world’s leading research institutes and universities as well as independent inventors.

Get in Touch:-
India Office
207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram, Haryana 122018, India
+91 124 429 4218

Email:-
contact@iebrain.com